Tatsushi Kodama

发表

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.

Hiroshi Sakamoto, H. Sakamoto, Miyuki Yoshida, 2014, Cancer letters.

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

Hiroshi Sakamoto, H. Sakamoto, T. Fukami, 2011, Cancer cell.

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

Hiroshi Sakamoto, H. Sakamoto, Tatsushi Kodama, 2014, Cancer Chemotherapy and Pharmacology.